Opendata, web and dolomites

CUSTOMI Arch

New materials for revolutionary, branched, non-supported stents (CUSTOMI™) for aortic-arch endovascular repair

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CUSTOMI Arch" data sheet

The following table provides information about the project.

Coordinator
ENDONOV 

Organization address
address: 19-21 RUE THALES DE MILET EMERGENCE TECHNOPOLE ET INCUBATEUR
city: LE MANS
postcode: 72000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.endonov.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENDONOV FR (LE MANS) coordinator 50˙000.00

Map

 Project objective

Aortic dissection and aneurysms are the two most common life-threatening disorders affecting the aorta. Unless they are treated immediately, they result in shock and death in 80% of cases. However, according to Prof. Koskas, today up to 50% of patients with a high surgical risk cannot be treated with traditional open surgery. This implies that new and less invasive interventions are urgently needed. This is not only a European challenge, but a global one that impacts patients worldwide. Endonov is developing a disruptive solution called the CUSTOMI® Arch Branched stent system to overcome these existing problems. New woven fabric materials and advanced manufacturing procedures are playing a crucial role in CUSTOMI®’s unique design and fabrication. For the first time, smaller, tailor-made and multi-branched stent-grafts will be able to take the shape of the complex aortic arch anatomy of each patient. This medical device will be implanted and positioned with greater precision using an advanced sensor guided delivery system. This will allow to treat much more patients with different arch anatomies and ensure a longer term durability of the device. Endovascular surgeons from the famous US Mayo Clinic have stated CUSTOMI® Arch is currently the only solution in development able to overcome the major problem of complex aortic arch morphology and anatomy. Endovascular repair technology for the aortic arch is a highly growing and emerging field. Endonov has a huge opportunity to market a new medical device that will benefit thousands of patients all over the world, effectively lowering lethal rates of aortic arch pathologies. The commercialization of the CUSTOMI® Arch will make Endonov the first European company and a worldwide leader in the field of endovascular aortic repair with an estimated turnover of about 67 million euros and the creation of 71 new high-level jobs in Europe by 2022.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CUSTOMI ARCH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CUSTOMI ARCH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Volumizer (2018)

A natural, non-surgical, and safe facial filler which treats the root cause of facial ageing.

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More